Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is the evaluation of sustained response rate after
discontinuation of treatment with TPO-RAs, Eltrombopag and Romiplostim, in persistent or
chronic pITP patients who failed one or more therapy lines, splenectomy included.